Comparison of captopril and enalapril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE inhibitors in high dieted methionine mice

Journal of Cardiovascular Pharmacology

Volumn 47, Issue 1, 2006, Pages 82-88

  Liu, Yu Hui ^a   Liu, Li Ying ^a   Wu, Jin Xiang ^a   Chen, Shuang Xiu ^a   Sun, Yin Xue ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Angiotensin converting enzyme; Captopril; Malondialdehyde; Methionine; Nitric oxide; Paraoxonase 1; Superoxide dismutase

Indexed keywords

ACETYLCHOLINE; ACETYLCYSTEINE; ARYLDIALKYLPHOSPHATASE 1; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; MALONALDEHYDE; METHIONINE; NITRIC OXIDE; SUPEROXIDE DISMUTASE; THIOL GROUP; VASODILATOR AGENT; ARYLDIALKYLPHOSPHATASE; THIOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; HYPERHOMOCYSTEINEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; SMOOTH MUSCLE RELAXATION; STRUCTURE ACTIVITY RELATION; VASCULAR ENDOTHELIUM; ANIMAL; BLOOD; COMPARATIVE STUDY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; VASODILATATION;

ACETYLCYSTEINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ARYLDIALKYLPHOSPHATASE; CAPTOPRIL; ENALAPRIL; ENDOTHELIUM, VASCULAR; MALE; MALONDIALDEHYDE; METHIONINE; NITRIC OXIDE; PEPTIDYL-DIPEPTIDASE A; RATS; RATS, SPRAGUE-DAWLEY; SULFHYDRYL COMPOUNDS; SUPEROXIDE DISMUTASE; VASODILATION;

EID: 33646680300     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000195306.61719.64     Document Type: Article

References (34)

1. Durand P, Prost M, Loreau N, et al. Impaired homocysteine metabolism and atherothrombotic disease. Lab Invest. 2001;81:645-672.
2. Judith W, Cook Lloyd M, et al. Homocysteine and arterial disease. Experimental mechanisms. Vasc Pharmacol. 2002;38:293-300.
3. Kanini PM, Sinkey CA, Browning RL, et al. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation. 1999;100:1161-1168.
4. Mutus B, Rabini RA, Staffolani R, et al. Homocysteine-induced inhibition of nitric oxide production in platelets: a study on healthy and diabetic subjects. Diabetologia. 2001;44:979-982.
5. Cipolla MJ, Williamson WK, Nehler ML, et al. The effect of elevated homocysteine level on vasoconstriction of human resistance arteries: the role of the endothelium and reactive oxygen species. J Vasc Surg. 2000;31:751-759.
6. Jakubowski H. Molecular basis of homocysteine toxicity in humans. Cell Mol Life Sci. 2004;61:470-487.
7. Jakubowski H, Zhang L, Bardeguze A, et al. Homocysteine thiolactone and protein homocysteinylation in human endothelial cells: implications for atherosclerosis. Circ Res. 2000;87:45-51.
8. Naruszewicz M, Mirkiewicz E, Oleszewski AJ, et al. Thiolation of low-density lipoprotein by homocysteine- thiolactone causes increased aggregation and interaction with cultured macrophages. Nutr Metab Cardiovasc Dis. 1994;4:70-77.
9. Ferretti G, Bacchetti T, Moroni C, et al. Effect of homocysteinylation of low density lipoproteins on lipid peroxidation of human endothelial cells. J Cell Biochem. 2004;92:351-360.
10. Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J Biol Chem. 2000;275:3957-3962.
11. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21:473-480.
12. Jakubowski H, Ambrosius WT, Pratt JH. Genetic determinants of homocysteine thiolactonase activity in humans: implications for atherosclerosis. FEBS Lett. 2001;491:35-39.
13. Vavrinkova H, Tutterova M, Stopka P, et al. The effect of Captopril on nitric oxide formation and on generation of radical forms of mitochondrial respiratory chain compounds in ischemic rat heart. Physiol Res. 2001;50:481-489.
14. Keaton AK, White CR, Berecek KH. Captopril treatment and its withdrawal prevents impairment of endothelium-dependent responses in the spontaneously hypertensive rat. Clin Exp Hypertens. 1998;20:847-866.
15. Fu YF, Xiong Y, Fu SH. Captopril restores endothelium-dependent relaxation of rat aortic rings after exposure to homocysteine. J Cardiovasc Pharmacol. 2003;42:566-572.
16. Chao CL, Lee YT. Impairment of cerebrovascular reactivity by methionine-induced hyperhomocysteinemia and amelioration by quinapril treatment. Strole. 2000;31:2907-2911.
17. Ma FX, Liu LY, Xiong XM. Protective effects of lovastatin on vascular endothelium injured by low density lipoprotein. Acta Pharmacol Sin. 2003;24:1027-1032.
18. Wu HT, Xiong XM, Wang SX, et al. Protective effect of extract of leaves of ginkgo biloba on hyperlipidemia-induced vascular disfunction of rats and its relation with preservation of PON-1 activity. Chin J Arterioscler. 2004;4:410-414.
19. Lang D, Kredan M, Moat S, et al. Homocysteine-induced inhibition of endothelium-dependent relaxation in rabbit aorta - role for superoxide anions. Arterioscler Thromb Vasc Biol. 2000;20:422-427.
20. Mansoor MA, Bergmark C, Svardal AM, et al. Redox status and protein binding of plasma homocyst(e)ine and other aminothiols in patients with early-onset peripheral vascular disease. Arterioscler Thromb Vasc Biol. 1995;15:232-240.
21. Landmesser U, Drexler H. Oxidative stress, the renin-angiotensin system, and atherosclerosis. Eur Heart J Suppl. 2003;5(Suppl A):A3-A7.
22. Lonn E. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in atherosclerosis. Curr Atheroscler. 2002;4:363-372.
23. Keidar S, Attias J, Coleman R, et al. Attenuation of atherosclerosis in apolipoprotein E-deficient mice by ramipril is dissociated from its antihypertensive effect and from potentiation of bradykinin. J Cardiovasc Pharmacol. 2000;35:64-72.
24. Napoli C, Cicala C, D'Armiento FP, et al. Beneficial effects of ACE-inhibition with zofenopril on plaque formation and low-density lipoprotein oxidation in Watanabe heritable hyperlipidemic rabbits. Gen Pharmacol. 1999;33:467-477.
25. de Nigris F, D'Armiento FP, Somma P, et al. Chronic treatment with sulfhydryl angiotensin-converting enzyme inhibitors reduce susceptibility of LDL to in vitro oxidation, formation of oxidation-specific epitopes in the arterial wall, and atherogenesis in apolipoprotein E knockout mice. Int J Cardiol. 2001;81:107-115.
26. Fu YF, Xiong Y, Guo Z. A reduction of endogenous asymmetric dimethylarginine contributes to the effect of Captopril on endothelial dysfunction induced by homocysteine in rats. Eur J Pharmacol. 2005; 508:167-175.
27. Mak IT, Freedman AM, Dickens BF, et al. Protective effects of sulfhydryl-containing angiotensin-converting enzyme inhibitors against free radical injury in endothelial cells. Biochem Pharmacol. 1990;40: 2169-2175.
28. Napoli C, Ignarro LJ. Nitric oxide and atherosclerosis. Nitric Oxide. 2001;5:88-97.
29. Chopra M, Beswick H, Clapperton M, et al. Antioxidant effects of angiotensin-converting enzyme (ACE) inhibitors: free radical and oxidant scavenging are sulfhydryl dependent, but lipid peroxidation is inhibited by both sulfhydryl- and nonsulfhydryl-containing ACE inhibitors. J Cardiovasc Pharmacol. 1992;19:330-340.
30. Napoli C, Sica V, De Nigris F, et al. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J. 2004;148:e5-e11.
31. Shih DM, Gu L, Xia Y-R, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 1998;394:284-287.
32. Aviram M, Billecke S, Sorenson R, et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different than that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol. 1998;18:1617-1624.
33. Aviram M, Rosenblat M, Billecke S, et al. Human serum paraoxonase (Pon 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med. 1999;26:892-904.
34. Hayek T, Pavlotzky R, Hamoud S, et al. Tissue angiotensin-converting- enzyme (ACE) deficiency leads to a reduction in oxidative stress and in atherosclerosis studies in ACE-knockout mice type 2. Arterioscler Thromb Vasc Biol. 2003;23:2090-2096.